Background/Aims: Calciphylaxis is associated with a poor prognosis in dialysis patients, and its pathogenesis remains incompletely understood. Although the use of vitamin K antagonists (VKA) has been implicated, previous reports are conflicting. We aimed to determine if vitamin K antagonists conferred an increased risk of calciphylaxis in patients on dialysis. Methods: We performed a single-centre, retrospective cohort study of 2,234 patients receiving dialysis, and compared the characteristics of those with and without calciphylaxis. Results: We identified 5 cases of calciphylaxis (all female) between January 2009 and December 2013. Overall, 142 patients (6.4%) were treated with VKA during the study period. Calciphylaxis was more common in the VKA group (4 of 142 patients, OR = 61, 95% CI 6.7-546, p = 0.0001). VKA was withdrawn in all cases and treatment instituted with sodium thiosulphate, cinacalcet and supportive measures. All patients recovered, although there was one sudden cerebrovascular death during follow-up. Conclusion: Treatment with VKA predisposes to the development of calciphylaxis.

Keywords:
Calciphylaxis, Calcific, Uremic, Arteriolopathy, Warfarin, Dialysis
1.
Brandenburg VM, Cozzolino M, Ketteler M: Calciphylaxis: a still unmet challenge. J Nephrol 2011;24:142-148.
2.
Mazhar AR, Johnson RJ, Gillen D, et al: Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int 2001;60:324-332.
3.
Lal G, Nowell AG, Liao J, Sugg SL, Weigel RJ, Howe JR: Determinants of survival in patients with calciphylaxis: a multivariate analysis. Surgery 2009;146:1028-1034.
4.
Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR: Calciphylaxis: natural history, risk factor analysis, and outcome. J Am Acad Dermatol 2007;56:569-579.
5.
Nigwekar SU, Wolf M, Sterns RH, Hix JK: Calciphylaxis from nonuremic causes: a systematic review. Clin J Am Soc Nephrol 2008;3:1139-1143.
6.
Nigwekar SU, Solid CA, Ankers E, Malhotra R, Eggert W, Turchin A, et al: Quantifying a rare disease in administrative data: the example of calciphylaxis. J Gen Intern Med 2014;29(suppl 3):S724-S731.
7.
Shanahan CM: Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol 2013;9:661-670.
8.
Weenig RH: Pathogenesis of calciphylaxis: Hans Selye to nuclear factor kappa-B. J Am Acad Dermatol 2008;58:458-471.
9.
Schlieper G, Westenfeld R, Kruger T, Cranenburg EC, Magdeleyns EJ, Brandenburg VM, et al: Circulating nonphosphorylated carboxylated matrix gla protein predicts survival in ESRD. J Am Soc Nephrol 2011;22:387-395.
10.
Krueger T, Schlieper G, Schurgers L, Cornelis T, Cozzolino M, Jacobi J, et al: Vitamin K1 to slow vascular calcification in haemodialysis patients (VitaVasK trial): a rationale and study protocol. Nephrol Dial Transplant 2014;29:1633-1638.
11.
Beazley KE, Eghtesad S, Nurminskaya MV: Quercetin attenuates warfarin-induced vascular calcification in vitro independently from matrix Gla protein. J Biol Chem 2013;288:2632-2640.
12.
Rennenberg RJ, van Varik BJ, Schurgers LJ, et al: Chronic coumarin treatment is associated with increased extracoronary arterial calcification in humans. Blood 2010;115:5121-5123.
13.
Asobie N, Wong E, Cook MG: Calciphylaxis in a diabetic patient provoked by warfarin therapy. Clin Exp Dermatol 2008;33:342-344.
14.
Salmhofer H, Franzen M, Hitzl W, Koller J, Kreymann B, Fend F, et al: Multi-modal treatment of calciphylaxis with sodium-thiosulfate, cinacalcet and sevelamer including long-term data. Kidney Blood Press Res 2013;37:346-359.
15.
Nigwekar SU, Bhan I, Turchin A, Skentzos SC, Hajhosseiny R, Steele D, et al: Statin use and calcific uremic arteriolopathy: a matched case-control study. Am J Nephrol 2013;37:325-332.
16.
Fine A, Zacharias J: Calciphylaxis is usually non-ulcerating: risk factors, outcome and therapy. Kidney Int 2002;61:2210-2217.
17.
Woolf B: On estimating the relation between blood group and disease. Ann Hum Genet 1955;19:251-253.
18.
Crotty R, Nazarian RM, Song PI, Van Cott EM: Heparin, warfarin, or calciphylaxis? Am J Hematol 2014;89:785-786.
19.
Shah M, Avgil Tsadok M, Jackevicius CA, et al: Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis. Circulation 2014;129:1196-1203.
20.
Angelis M, Wong LL, Myers SA, Wong LM: Calciphylaxis in patients on hemodialysis: a prevalence study. Surgery 1997;122:1083-1089; discussion 1089-1090.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.